A study in Journal of Neuroinflammation reports a mechanism shift for teriflunomide: the multiple sclerosis drug appears to ameliorate disease through direct inhibition of the NLRP3 inflammasome rather than solely via its traditional dihydroorotate dehydrogenase pathway explanation. The authors report direct binding of teriflunomide to NLRP3 and suppression of NLRP3 ATPase activity, blocking inflammasome assembly. The paper links this mechanistic claim to measurable immunology in patients with multiple sclerosis, where teriflunomide reduced circulating IL-1β levels. The team also reported effects across other inflammation-driven models, including monosodium urate-induced peritonitis and gouty arthritis. For drug developers, the work reinforces how repositioning and mechanism clarification can open expansion opportunities beyond the original indication while also sharpening biomarker expectations for NLRP3 pathway modulation.
Get the Daily Brief